Completed PHASE2 INTERVENTIONAL 2-arm NCT02111161

Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial (INSTINCT)

Sponsor: Anders Perner

Conditions Fournier Gangrene Gas Gangrene Necrotizing Fasciitis Necrotizing Soft Tissue Infection

Interventions IVIG (Privigen) Saline 0.9%

Updated 5 times since 2017 Last updated: Sep 29, 2016 Started: Apr 30, 2014 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Fournier Gangrene and Gas Gangrene, this trial is completed. The trial is conducted by Anders Perner and has accumulated 5 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anders Perner
CSL Behring

Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark